Suppr超能文献

相似文献

2
Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice.
Hum Gene Ther. 2012 Dec;23(12):1269-79. doi: 10.1089/hum.2012.056. Epub 2012 Sep 24.
4
Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
Science. 2004 Dec 3;306(5702):1796-9. doi: 10.1126/science.1104297. Epub 2004 Nov 4.
5
AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy.
Mol Ther. 2013 Aug;21(8):1551-8. doi: 10.1038/mt.2013.121. Epub 2013 Jun 11.
7
[Gene therapy for muscular dystrophy].
No To Hattatsu. 2004 Mar;36(2):117-23.
8
Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice.
PLoS One. 2010 Feb 11;5(2):e9176. doi: 10.1371/journal.pone.0009176.

引用本文的文献

2
Therapeutic applications and challenges in myostatin inhibition for enhanced skeletal muscle mass and functions.
Mol Cell Biochem. 2025 Mar;480(3):1535-1553. doi: 10.1007/s11010-024-05120-y. Epub 2024 Sep 28.
3
Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients.
Int J Mol Sci. 2024 Aug 12;25(16):8763. doi: 10.3390/ijms25168763.
4
Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular Dystrophy.
Neurol Int. 2024 Jul 5;16(4):731-760. doi: 10.3390/neurolint16040055.
6
The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy.
Neurol Ther. 2024 Feb;13(1):183-219. doi: 10.1007/s40120-023-00570-w. Epub 2024 Jan 8.
7
Therapeutic approaches for Duchenne muscular dystrophy.
Nat Rev Drug Discov. 2023 Nov;22(11):917-934. doi: 10.1038/s41573-023-00775-6. Epub 2023 Aug 31.
8
Myostatin: a potential therapeutic target for metabolic syndrome.
Front Endocrinol (Lausanne). 2023 May 23;14:1181913. doi: 10.3389/fendo.2023.1181913. eCollection 2023.
9
Longitudinal Assessment of Creatine Kinase, Creatine/Creatinine, and Myostatin as Monitoring Biomarkers in Becker Muscular Dystrophy.
Neurology. 2023 Feb 28;100(9):e975-e984. doi: 10.1212/WNL.0000000000201609. Epub 2022 Dec 5.

本文引用的文献

4
Molecular, cellular and physiological investigation of myostatin propeptide-mediated muscle growth in adult mice.
Neuromuscul Disord. 2009 Jul;19(7):489-99. doi: 10.1016/j.nmd.2009.06.367. Epub 2009 Jun 21.
6
Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activity.
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7479-84. doi: 10.1073/pnas.0811129106. Epub 2009 Apr 21.
7
Muscle involvement and IGF-1 signaling in genetic disorders: new therapeutic approaches.
Endocr Dev. 2009;14:29-37. doi: 10.1159/000207474. Epub 2009 Feb 27.
8
Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs.
Ann Neurol. 2009 Jun;65(6):667-76. doi: 10.1002/ana.21627.
10
A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy.
Ann Neurol. 2008 May;63(5):561-71. doi: 10.1002/ana.21338.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验